Preprint Review Version 1 This version is not peer-reviewed

Actionable Molecular Pathways in Colorectal Cancer

Version 1 : Received: 28 October 2024 / Approved: 28 October 2024 / Online: 30 October 2024 (07:52:05 CET)

How to cite: Duta-Ion, S. G.; Juganaru, I. R.; Hotinceanu, I. A.; Dan, A.; Burtavel, L. M.; Coman, M. C.; Focsa, I. O.; Zaruha, A. G.; Codreanu, P. C.; Bohiltea, L. C.; Rădoi, V. E. Actionable Molecular Pathways in Colorectal Cancer. Preprints 2024, 2024102231. https://doi.org/10.20944/preprints202410.2231.v1 Duta-Ion, S. G.; Juganaru, I. R.; Hotinceanu, I. A.; Dan, A.; Burtavel, L. M.; Coman, M. C.; Focsa, I. O.; Zaruha, A. G.; Codreanu, P. C.; Bohiltea, L. C.; Rădoi, V. E. Actionable Molecular Pathways in Colorectal Cancer. Preprints 2024, 2024102231. https://doi.org/10.20944/preprints202410.2231.v1

Abstract

Colorectal cancer (CRC) arises through a combination of genetic and epigenetic alterations that affect key pathways involved in tumor growth and progression. This review examines the major molecular pathways driving CRC, including Chromosomal Instability (CIN), Microsatellite Instability (MSI), and the CpG Island Methylator Phenotype (CIMP). Key mutations in genes such as APC, KRAS, NRAS, BRAF, and TP53 activate signaling pathways like Wnt, EGFR, and PI3K/AKT, contributing to tumorigenesis and influencing responses to targeted therapies. Resistance mechanisms, including mutations that bypass drug action, remain challenging in CRC treatment. The review highlights the role of molecular profiling in guiding the use of targeted therapies such as tyrosine kinase inhibitors and immune checkpoint inhibitors. Novel combination treatments are also discussed as strategies to improve outcomes and overcome resistance. Understanding these molecular mechanisms is critical to advancing personalized treatment approaches in CRC and improving patient prognosis.

Keywords

colon cancer; targeted therapy; immunotherapy; BRAF mutations; MSI/dMMR; PI3K/AKT/mTOR pathway; KRAS mutations; APC pathway

Subject

Medicine and Pharmacology, Oncology and Oncogenics

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.